| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 07/25/2002 | WO2001070798A3 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 07/25/2002 | WO2001055176A3 Methods for inhibiting smooth muscle cell proliferation |
| 07/25/2002 | US20020099209 Dihydrostilbene alkanoic acid derivatives |
| 07/25/2002 | US20020099191 EDG8 receptor, its preparation and use |
| 07/25/2002 | US20020099068 I kappa B kinase inhibitors for treating various disorders including arthritis |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | US20020098237 Neurotoxin implant |
| 07/25/2002 | US20020098201 Novel myxoma genes for immune modulation |
| 07/25/2002 | CA2435260A1 Receptors and membrane-associated proteins |
| 07/25/2002 | CA2434939A1 Urea derivatives as integrin alpha 4 antagonists |
| 07/25/2002 | CA2434636A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (adp-ribose) glycohydrolase, and methods for their use |
| 07/25/2002 | CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | CA2433313A1 Polypetides and nucleic acids encoding same |
| 07/25/2002 | CA2432776A1 Isoindolyl and isoquinolinyl aroyl pyrrole compounds |
| 07/25/2002 | CA2430634A1 Proteins, polynucleotides encoding them and methods of using the same |
| 07/24/2002 | EP1224932A1 Drugs inhibiting cell death |
| 07/24/2002 | EP1224322A2 Gene sequence variations with utility in determining the treatment of disease |
| 07/24/2002 | EP1224285A2 27 human secreted proteins |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224218A1 Dna encoding human alpha1g-c t-type calcium channel |
| 07/24/2002 | EP1224209A1 10 human secreted proteins |
| 07/24/2002 | EP1224207A1 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/24/2002 | EP1224206A1 Sapogenin derivatives and their use in the treatment of cognitive dysfunction |
| 07/24/2002 | EP1224205A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224200A1 Tissue plasminogen activator-like protease |
| 07/24/2002 | EP1224182A1 N-substituted 1-(lactone) isoquinolones for treating nervous disorders |
| 07/24/2002 | EP1224180A2 Substituted azoles |
| 07/24/2002 | EP1224179A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/24/2002 | EP1224175A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224174A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224163A1 Use of carbonylamino derivatives against cns disorders |
| 07/24/2002 | EP1223961A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 07/24/2002 | EP1223915A1 Dry powder compositions having improved dispersivity |
| 07/23/2002 | US6423708 Aralkyl and aralkylidene heterocyclic lactams and imides |
| 07/23/2002 | US6423319 Methods for treating muscle injuries |
| 07/18/2002 | WO2002055678A1 Extramedullary adipose tissue cells and use thereof for regenerating hematopoietic and muscular tissues |
| 07/18/2002 | WO2002055547A2 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | WO2002055541A2 Peptides having inhibiting activity on the production of nitric oxide |
| 07/18/2002 | WO2002055524A1 THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 07/18/2002 | WO2002055501A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | WO2002055481A1 Prodrugs of excitatory amino acids |
| 07/18/2002 | WO2002055108A1 Targeted modification of intracellular compounds |
| 07/18/2002 | WO2002055099A2 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| 07/18/2002 | WO2002055075A2 Compounds and methods for regulating cell differentiation |
| 07/18/2002 | WO2002055064A2 Mucopolysaccharidosis therapies |
| 07/18/2002 | WO2002029088A3 Highly expressible genes |
| 07/18/2002 | WO2002022558A3 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 07/18/2002 | WO2002013758A3 System for regulating in vivo the expression of a transgene by conditional inhibition |
| 07/18/2002 | WO2002002633A3 Transporters and ion channels |
| 07/18/2002 | WO2001094391A3 Intracellular signaling proteins |
| 07/18/2002 | WO2001088134A3 Novel human lipocalin homologs and polynucleotides encoding the same |
| 07/18/2002 | WO2001083480A3 Dihydropyridine compounds and methods of use |
| 07/18/2002 | WO2001081590A3 Protein phosphatases |
| 07/18/2002 | WO2001079282A3 Molecules associated with human reproduction |
| 07/18/2002 | WO2001049295A9 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 07/18/2002 | WO2001044514A3 Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements |
| 07/18/2002 | WO2001005834A9 Human tumor necrosis factor receptors tr13 and tr14 |
| 07/18/2002 | US20020095024 B7-related nucleic acids and polypeptides useful for immunomodulation |
| 07/18/2002 | DE10102053A1 Piperazinylcarbonyl-quinoline and piperazinylcarbonyl-isoquinoline derivatives useful for treatment of e.g. schizophrenia, psychoses, depression, Parkinson's disease and Alzheimer's disease |
| 07/18/2002 | CA2434672A1 Sfrp and peptide motifs that interact with sfrp and methods of their use |
| 07/18/2002 | CA2434274A1 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them |
| 07/18/2002 | CA2434005A1 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists |
| 07/18/2002 | CA2430588A1 Modulation of pericyte proliferation using bpi protein products or bpi inhibitors |
| 07/18/2002 | CA2428497A1 Targeted modification of intracellular compounds |
| 07/17/2002 | EP1222459A1 Crystallographic structure of the androgen receptor ligand binding domain |
| 07/17/2002 | EP1222270A2 Proteins and polynucleotides encoded thereby |
| 07/17/2002 | EP1222206A1 Pablo, a polypeptide that interacts with bcl-xl, and uses related thereto |
| 07/17/2002 | EP1222201A2 Peptides which stimulate the immune response and tissue regeneration |
| 07/17/2002 | EP1221973A1 CD40 antagonist for treating psoriasis |
| 07/17/2002 | EP1221941A1 Powder pharmaceutical formulations |
| 07/17/2002 | EP1221939A1 Ortho ester lipids |
| 07/17/2002 | EP0979224B1 Solid compositions suitable for oral administration comprising l-carnitine or alkanoyl-l-carnitine magnesium fumarate |
| 07/17/2002 | CN1359289A Selective iGLuR5 receptor antagonists for the treatment of migraine |
| 07/17/2002 | CN1359288A Method for improvement of transport across adaptable semi-permeable barriers |
| 07/17/2002 | CN1358543A Recombination plasmid and application in disease prevention and control |
| 07/17/2002 | CN1358530A Litholytic medicine for treating hepatolith and preparation process thereof |
| 07/16/2002 | US6420408 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| 07/16/2002 | US6420395 Disorders or diseases involving the cholinergic system of the central nervous system, pain, inflammatory diseases, diseases caused by smooth muscle contractions and as assistance in the cessation of chemical substance abuse. |
| 07/16/2002 | US6420385 Substituted pyrimidinone and pyridone compounds and methods of use |
| 07/16/2002 | US6420364 Treating autoimmune diseases,alzheimer's disease, atherosclerosis, osteoporosis, |
| 07/16/2002 | US6420353 Use of 7 α-substituted steroid to treat neuropsychiatric, immune or endocrine disorders |
| 07/16/2002 | US6420342 Ribose, folic acid, orotic acid |
| 07/16/2002 | CA2131383C Wound healing and treatment of fibrotic disorders |
| 07/11/2002 | WO2002053580A2 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 07/11/2002 | WO2002053159A1 Neurotrophic tacrolimus analogs |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002052957A1 Creatine/citric acid compound, method for the production of the same and the use thereof |
| 07/11/2002 | WO2002036605A3 Estrone-derivatives having cytoprotective activity |
| 07/11/2002 | WO2002030354A3 Uridine therapy for patients with elevated purine levels |
| 07/11/2002 | WO2002017914A8 Fused pyrrolocarbazoles against inflammation |
| 07/11/2002 | WO2001044473A3 Polypeptides and nucleic acids encoding same |
| 07/11/2002 | WO2001040187A3 Compound having effect of promoting neuron differentiation |
| 07/11/2002 | WO2001025438A3 Ifn-alpha homologues |
| 07/11/2002 | WO2001020969A3 Use of ribose to prevent cramping and soreness in muscles |
| 07/11/2002 | WO2000075144A9 Peroxynitrite decomposition catalysts and methods of use thereof |
| 07/11/2002 | US20020091240 Humanized antibodies to gamma-interferon |
| 07/11/2002 | US20020091136 Pharmaceutical compositions containing cinchonine dichlorhydrate |
| 07/11/2002 | US20020091105 Useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. |
| 07/11/2002 | US20020090695 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |